-
Product Insights
Neuroblastoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Neuroblastoma Clinical Trials Market Report Overview There were a total of 680 neuroblastoma clinical trials conducted as of January 2023. The neuroblastoma clinical trial market research report provides a comprehensive overview of the market across regions and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. The report includes information about the sponsor types and the prominent sponsors associated with the trials as well. Neuroblastoma Clinical Trials Market Segmentation by Regions...
-
Sector Analysis
B-Cell Non-Hodgkin Lymphoma (NHL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
B-Cell Non-Hodgkin Lymphoma (NHL) Marketed and Pipeline Drugs Market Report Overview B-cell NHL generally arises in the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen, and can disseminate to involve distant sites such as the lung or brain in the later stages of the disease. NHLs are further categorized into indolent or aggressive prognostic subtypes, which further influence outcomes and treatment decisions. The B-Cell NHL marketed, and pipeline drugs market research report includes an assessment of...
-
Sector Analysis
Acute Lymphocytic Leukemia (ALL) - Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Acute Lymphocytic Leukemia Cell Therapy Market Overview The total market value for the 15M, which includes both cell therapies and established/traditional ALL therapies was $2.3 billion in 2021. The need for “off-the-shelf” products with lower costs and reduced infrastructure requirements raises the development of allogeneic agents thereby driving the market growth. Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Know More about the Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market...
-
Sector Analysis
Chronic Lymphocytic Leukemia (CLL) - Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Report Overview The total market value for the 15MM, which includes both cell therapies and established/traditional CLL therapies was $13.2 billion in 2021. Allogeneic stem cell transplant is becoming less popular due to high levels of morbidity and CAR-T seems an attractive replacement to induce long-term disease control. Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Know More about Chronic Lymphocytic Leukemia (CLL)...
-
Sector Analysis
Multiple Myeloma - Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Multiple Myeloma Cell Therapy Market Report Overview The total market value for the 15M, which includes both cell therapies and established/traditional MM therapies was $25.7 billion in 2021. The following are some of the key highlights of the multiple myeloma cell therapy market: The market growth will be attributed to the established CAR-T agents such as Abecma and Carvykt. The success of CAR-Ts in MM has fueled R&D investment into this class of therapy, with more CAR-Ts in development than...
-
Sector Analysis
Bladder Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Bladder Cancer Pipeline Drugs Analysis Report Overview There are 13 marketed innovator therapies for bladder cancer, with an almost equal number of small molecules and biologics. The Bacillus Calmette-Guerin (BCG) vaccine is considered a gold-standard therapy in high-risk NMIBC (non-muscle-invasive bladder cancer) patients. The bladder cancer marketed and pipeline drugs market research report provides a data-driven overview of the current and future competitive landscape in bladder cancer therapeutics. This report includes an assessment of the disease epidemiology, leading marketed products...
-
Product Insights
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...
-
Product Insights
Multiple Myeloma (Kahler Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Myeloma Pipeline Products Market Report Overview Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. It mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain, and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery. The Multiple Myeloma Drugs in Development market research...
-
Product Insights
Medulloblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Medulloblastoma Pipeline Drugs Market Report Overview Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occurs in the cerebellum, which is the part of the brain located at the base of the skull, just above the brainstem. Symptoms associated with a Medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting, and difficulty walking and with balance. Medulloblastoma can spread to other areas of the central nervous system. Treatment includes options...
-
Product Insights
Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glioblastoma Multiforme Pipeline Drugs Market Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness, and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy, and chemotherapy. The Glioblastoma Multiforme (GBM) drugs in development market research report provides comprehensive information on the therapeutics under...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.